山东百龙创园生物科技股份有限公司股东减持股份结果公告

Group 1 - The core point of the announcement is the reduction of shareholding by major shareholders of Shandong Bailong Chuangyuan Biotechnology Co., Ltd., with a total of 16,928,000 shares being sold, representing 4.95% of the company's total share capital [1] - The shareholders involved in the reduction include Qingdao Enfu Kaijin Venture Capital Fund Partnership and its acting in concert, with a total shareholding of 40,343,524 shares before the reduction, accounting for 12.49% of the total share capital [1] - The reduction was executed through block trading, with Qingdao Enfu reducing 14,354,000 shares and Jiaxing Enfu reducing 2,574,000 shares [1] Group 2 - The company implemented a capital reserve conversion on June 11, 2025, increasing the total share capital from 323,086,400 shares to 420,012,320 shares by distributing 0.3 shares for every share held [2][3] - The reduction plan was completed as scheduled, and the actual reduction met the previously disclosed plan [3]